Novo Nordisk A/S - share repurchase programme
10 juin 2024 08h15 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 10 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Novo Nordisk A/S - share repurchase programme
03 juin 2024 10h05 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 3 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Novo Nordisk A/S - share repurchase programme
27 mai 2024 08h49 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 27 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Novo Nordisk A/S - share repurchase programme
17 mai 2024 10h20 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 17 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
15 mai 2024 07h23 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 15 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons...
Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial
13 mai 2024 11h49 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 13 May 2024 – Novo Nordisk today announced the headline results from the FRONTIER 2 trial, a pivotal phase 3a, 26-week open-label, randomised, controlled, multi-arm trial in 254...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
08 mai 2024 11h31 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 8 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons...
Trading in Novo Nordisk shares by board members, executives and associated persons
06 mai 2024 15h02 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 06 May 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons...
Novo Nordisk A/S - share repurchase programme
06 mai 2024 14h44 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 06 May 2024 – The execution of Novo Nordisk A/S’ overall share repurchase programme for 2024 of DKK 20 billion continues. As part of this, Novo Nordisk A/S has now initiated a new...
Novo Nordisk A/S purchases B shares worth DKK 5,428 million from Novo Holdings A/S under the 2024 share repurchase programme
06 mai 2024 14h40 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 06 May 2024 – Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 5,427,801,225.00 million from Novo Holdings A/S. The...